Introduction {#s1}
============

*Sox* genes encode an important group of transcription factors with relevant roles in many aspects of pre- and post-natal development of vertebrates and other animal taxa. There are 20 *Sox* genes in vertebrates, which are classified into 9 groups. *Sox8, Sox9,* and *Sox10 (SoxE* group) are involved in many developmental processes (reviewed in [@bib24]). All three *SoxE* genes are expressed during testis development, *Sox9* being essential for testis determination and *Sox9/Sox8* necessary for subsequent embryonic differentiation ([@bib8], [@bib2], [@bib4]). *Sox10* can substitute for *Sox9* during testis determination ([@bib36]). Undifferentiated gonads have the inherent potential to develop into two completely different organs, either as testes or as ovaries. The decision as to which fate to follow depends on the presence/absence of sex-specific factors. In the male, the Y-linked, mammalian sex-determining factor, *SRY*, upregulates *SOX9* which triggers testis differentiation, whereas in the female, the WNT/β -catenin signaling pathway becomes active and induces ovarian development ([@bib45]; reviewed in [@bib52]; [@bib46]). Both pathways antagonize each other: the loss of either *SRY or SOX9* leads to the formation of XY ovaries ([@bib6]; [@bib16]; [@bib57]) whereas the absence of WNT-signaling molecules such as WNT4 or RSPO1 causes XX sex reversal ([@bib55]; [@bib35]). Similarly, gain-of-function experiments confirmed this antagonism, as either upregulation of the testis promoting genes *Sox9* or *Dmrt1* in the XX bipotential gonad ([@bib7]; [@bib56]; [@bib60]) or ectopic activation of the canonical WNT signaling pathway in the XY bipotential gonad ([@bib26]) leads to XX and XY sex reversal, respectively. Furthermore, Sertoli cell-specific conditional inactivation of *Sox9* on a *Sox8^-/- ^*background at embryonic day 13.5 (E13.5), two days after the sex determination stage, leads to *Dmrt1* downregulation with upregulation of the ovarian-specific genes *Wnt4, Rspo1* and *Foxl2* ([@bib4]; [@bib19]). Similarly, Sertoli cell-specific ablation of *Dmrt1* at the same stage (E13.5) results in ectopic expression of *Foxl2* by postnatal day 14 (P14) and to *Sox9* downregulation by P28, including male-to-female genetic reprogramming, as revealed by mRNA profiling ([@bib28]). Again, gain-of-function experiments confirmed the existence of sexual antagonism after the sex determination period, as conditional stabilization of *β-catenin* in differentiated embryonic Sertoli cells (E13.5, *Amh-Cre*) resulted in testis cord disruption ([@bib9]). The male-vs-female genetic antagonism also persists in the adult ovary. The finding that in adult fertile females granulosa cells transdifferentiate into Sertoli-like cells after *Foxl2* ablation revealed that terminally differentiated female somatic cells require permanent repression of the male-promoting factors to maintain correct identity and function ([@bib54]). Furthermore, transgenic expression of *Dmrt1* in the adult ovary silenced *Foxl2* and transdifferentiated granulosa cells into Sertoli-like, *Sox9*-expressing cells ([@bib25]).

Regarding the adult testis, a similar phenomenon appears to occur in fully functional Sertoli cells after *Dmrt1* ablation ([@bib28]). In addition to cells with a Sertoli cell morphology expressing both SOX9 and FOXL2, some cells with typical granulosa cell features were also observed, including the absence of SOX9 and the presence of FOXL2. However, Sertoli-to-granulosa cell transdifferentiation was not unambiguously documented, as the authors used an inducible ubiquitous promoter (*UBC-CreERT2*) for *Dmrt1* ablation in adult Sertoli cells and the possible existence of genetic reprogramming was not investigated as no mRNA profiling was performed in adult mutant testes.

Nothing is known on the role of SOX9 in the adult testis, where it is expressed by Sertoli cells in a spermatogenic stage-dependent manner in several mammalian species ([@bib17]; [@bib13]; [@bib27]). Here we report the use of two Sertoli-cell-specific *Cre* lines (*Wt1-CreERT2* and *Sox9-CreERT2*) to induce *Sox9* ablation on a *Sox8^-/- ^*background in the adult testis, starting at postnatal day 60 (P60). We show that *Sox9/8* Sertoli cell-specific knockout (SC-DKO) testes undergo testis-to-ovary genetic reprogramming and Sertoli-to-granulosa cell transdifferentiation. The process is retinoic acid (RA)-mediated and occurs as a consequence of *Dmrt1* downregulation. SOX9/8 are necessary to maintain *Dmrt1* expression and thus to prevent *Foxl2* expression in the adult testis. Furthermore, double mutant testes exhibited complete degeneration of the seminiferous tubules and increased apoptosis, indicating that SOX9/8 are continually required for the maintenance of testis integrityy.

Results {#s2}
=======

*Sox9* and *Sox8* are necessary for maintaining the function and integrity of adult seminiferous tubules {#s2-1}
--------------------------------------------------------------------------------------------------------

To investigate the function of *Sox9* and *Sox8* in the adult testis, we induced the Sertoli cell-specific ablation of *Sox9* in adult *Sox8* null mutant mice using the tamoxifen (TX)-inducible *Cre-loxP* mutagenesis system. We used two different *CreERT2* mouse lines, a *Wt1* knock-in line (*Wt1-CreERT2;* [@bib61]), and a *Sox9* BAC-transgenic line (*Sox9-CreERT2;* [@bib23]). To check the Cre recombination efficiency, we introduced the R26R-EYFP allele in both *Sox9-CreERT2* and *Wt1-CreERT2* double homozygous *Sox9/8* knockout (DKO) mutants. *Sox8/9* DKO mice fed with a TX-supplemented diet for a maximun of 30 days starting at P60 ([Figure 1A](#fig1){ref-type="fig"}) showed EYFP expression in a reduced number of Sertoli cells already 10 days after the beginning of TX administration (10 datx, P70) in the two *CreERT2* lines. The number of EYFP^+^ Sertoli cells increased in both lines at later time-points, the *Sox9-CreERT2 *line showing always a higher number of positive cells than the *Wt1-CreERT2* line. From P150 (90 datx) on, the EYFP signal occupied the whole area of the seminiferous tubule section ([Figure 1Ba](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). However, the fact that the cytoplasm of Sertoli cells is very large and complex in shape, together with the severe shrinkage that *Sox9/8* SC-DKO seminiferous tubules have undergone by this time, made it very difficult to identify individual EYFP^+^ cells in these testes. Hence we performed immunofluorescence for SOX9 and counted the number of SOX9^+^ cells per transversal testis cord section. At P90 (30 datx) all seminiferous tubules still contained many positive cells, but the number was clearly reduced by P120 (60 datx) and even more by P150 (90 datx), when some testis cords were completely devoid of SOX9^+^cells ([Figure 1Bb--c](#fig1){ref-type="fig"}, [Figure 1 ---figure supplement 1B](#fig1s1){ref-type="fig"}). At this later stage, the number of SOX9^+^ cells per seminiferous tubule cross section decreased to 15.39 ± 3.36 (37% reduction) in the testes of the *Wt1-CreERT2; Sox9^f/f^; Sox8^-/-^*\[*Sox9/8* DKO (*Wt1*)\] mice and to 7.49 ± 3.61 (69% reduction) in those of the *Sox9-CreERT2; Sox9^f/f^; Sox8^-/- ^*\[*Sox9/8* DKO (*Sox9*)\] mice, when compared to controls (24.31 ± 2.94) ([Figure 1Bd](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). The fact that the number of recombinant Sertoli cells lacking *Sox9* in these mutant mice continues decreasing for several weeks after the end of the period of TX administration (30 days) suggests that many newly recombined cells appear after that time (persistence of TX in the body) and that perhaps either the *Sox9* transcript or the protein, or both, are very stable in adult Sertoli cells, so that the gene product may remain for days or weeks in the cell after the gene ablation event. We also found that the reduction of SOX9^+^ cells varied among testis cords and among animals. We selected the most affected regions of the most affected individuals for further analyses.10.7554/eLife.15635.003Figure 1.*Sox9* and *Sox8* maintain the function and integrity of the adult mouse testis.(**A**) Diagram illustrating the time course of TX administration. Mice were fed with a TX-supplemented diet during one month, between P60 (0 datx) and P90 (30 datx). After this period, mice were fed with a normal diet. The main stages studied in this work are depicted. (**B**) Analysis of the Cre-recombination efficiency in *Sox9/8* DKO (*Sox9*) mice at p150 (90 datx). (a) EYFP is widely expressed in SC-DKO testis cords. At the same stage, the number of SOX9^+^ cells in the control (*Sox9^f/f^;Sox8^-/-^*) (b) is clearly higher than in the mutant (c). (d) Comparisons of the mean number of SOX9^+^ cells per transversal testis tubule section in control (*Sox9^f/f^;Sox8^-/-^*) and mutant testes. All pairwise comparisons provided statistically significant differences (two tail test, p\<0.001 in all cases). (**C**) Time-course of testis regression in *Sox9/8* DKO (*Sox9*) mice. Representative micrographs are shown for both TX-treated controls (*Sox9^f/f^;Sox8^-/-^*) (a--f) and *Sox9/8* DKO (*Sox9*) mice (g--l) between p70 (10 datx) and P180 (120 datx). T, normal seminiferous tubules; arrows indicate desquamated germ cells; asterisks mark testis tubules showing signs of degeneration (from enlarged lumen to Sertoli cell-only condition); STC, shrunken testis cords; ATC acellular testis cords. (**D**) Analysis of somatic (a--i and m--n) and germ cell (j--l) molecular markers. Immunofluorescence for LAMININ (a--c), ACTA2 (d--f) and CLAUDIN11 (g-- i) in both P150 (90 datx) TX-treated control (*Sox9^f/f^;Sox8^-/-^*) (a, d and g) and SC-DKO testes at P150 (90 datx) (b, e and h) and P180 (120 datx) (c, f and i). Arrows mark seminiferous tubule expression of ACTA2 (d and e) and Claudin11 (g and h); arrowheads mark arterial expression of ACTA2 (d--f). Asterisks mark testis cords lacking ACTA2 (f) or Claudin11 (i) expression. Double immunofluorescence for PCNA and DMC1 showing the time-course of spermatogenesis reduction in the testes of both P150 (90 datx) TX-treated control (*Sox9^f/f^;Sox8^-/-^*) (j) and P90 (30 datx) and P150 (90 datx) SC-DKO mice (k,l). Arrows mark spermatocytes showing colocalization of the two proteins; arrowheads mark proliferating spermatogonia expressing PCNA but not DMC1. Expression of P450SCC (green fluorescence) in Leydig cells of both TX-treated control (*Sox9^f/f^;Sox8^-/-^*) (m) and SC-DKO (n) testes at P150 (90 datx). Scale bars in Bc, Cl and Dn represent 100 µm for pictures in B, 50 µm for those in C and 50 µm for those in D, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.003](10.7554/eLife.15635.003)10.7554/eLife.15635.004Figure 1---source data 1.Comparison of the number of SOX9^+^ cells per testis tubule in both SC-DKO mutants and TX-treated controls (*Sox9^f/f^;Sox8^-/-^*).**DOI:** [http://dx.doi.org/10.7554/eLife.15635.004](10.7554/eLife.15635.004)10.7554/eLife.15635.005Figure 1---figure supplement 1.Analysis of the CRE-recombination efficiency in SC-DKO mice.(**A**) Immunostaining of the EYFP protein in mutant mice at different times-points after the initiation of the TX treatment. The number of cells expressing EYFP increases with time (from a to e and from f to j). (**B**) Immunostaining for SOX9 in control (*Sox9^f/f^;Sox8^-/-^*) (a, b and c) and SC-DKO testes (d--i) at different time points after the initiation the TX treatment. The number of SOX9^+^ cells decreases with time. Scale bar in Aj and Bi represents 100 μm in A and B respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.005](10.7554/eLife.15635.005)10.7554/eLife.15635.006Figure 1---figure supplement 2.Redundant role for *Sox9* and *Sox8* in the maintenance of adult testis cord architecture.Haematoxilin-eosin stained transversal sections of P120 testes (left column) and epididymides (right column) from control mice (**a**--**b**) and four different types of *Sox9/8* DKO (*Wt1*) mice differing in the number of *Sox9/8* mutant alleles 60 days after TX administration during 5 days with a feeding-gauge needle (**c**--**j**). Mutant mice exhibited various degrees of testis regression correlating with the number of mutated alleles. Double homozygote mutants exhibited the highest degree of testicular degeneration, with all seminiferous tubules transformed into sterile, solid testis cords (Ai). Seminiferous tubules from control testes were normal, whereas those from mutant mice showed several abnormalities including enlarged lumen (arrow in **c**), and different degrees of germ cell depletion (asterisks in **c**, **e**, **g**, and **i**). Only control epididymides contained abundant sperm (arrows in **b**), whereas those from mutant mice were completely sterile (**d**, **f**, **h**, and **j**). Correspondingly, the testis mass of mutant mice decreased as the number of *Sox9/8* mutant alleles increased in their genotypes (**k**). Scale bars shown in **j** represents 50 μm for all micrographs.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.006](10.7554/eLife.15635.006)10.7554/eLife.15635.007Figure 1---figure supplement 3.Relative abundance of the most relevant morphological features observed in the testes of P120 control and *Sox9/8* mutant mice differing in the number of *Sox9/8* mutant alleles 60 days after TX administration during 5 days with a feeding-gauge needle.Categories of relative abundance: (−) not present, (+) sporadic, (++) scarce, (+++) abundant, (++++) generalized.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.007](10.7554/eLife.15635.007)10.7554/eLife.15635.008Figure 1---figure supplement 4.Time course of the testis phenotype of control and SC-DKO (*Wt1*) mice.Representative micrographs of H&E stained sections of non-treated *Sox8*^-/-^ (**a**--**f**), TX-treated *Sox8*^-/-^ (**g**--**l**) and TX-treated *Sox8/9* DKO (*Wt1*) (**m**--**r**) mouse testis at different time-points. T, normal testis tubules; arrows indicate desquamated germ cells; asterisks mark testis tubules showing some degree of degeneration; double asterisk mark acellular interstitial space; STC shrunken testis cords. Scale bars in Ar represents 50 μm for all micrographs.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.008](10.7554/eLife.15635.008)10.7554/eLife.15635.009Figure 1---figure supplement 5.Relative abundance of the most relevant morphological features observed throughout the timecourse of testis regression in double *Sox8/Sox9* mutant mice.Categories of relative abundance: (−) not present, (+) sporadic, (++) scarce, (+++) abundant, (++++) generalized.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.009](10.7554/eLife.15635.009)10.7554/eLife.15635.010Figure 1---figure supplement 6.Functional status of the BTB in *Sox9/8* DKO testes.The location of a biotin tracer (red fluorescence) shows that the BTB is impermeable in the control (*Sox9^f/f^;Sox8^-/-^*) testis (**a**) as it did not enter into the adlumninal compartment of the seminiferous tubules, whereas it is permeable in the mutant (**b**), where the tracer can be seen also inside the tubules. Scale bar in b represent 50 μm for **a** and **b**.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.010](10.7554/eLife.15635.010)10.7554/eLife.15635.011Figure 1---figure supplement 7.Expression bar plots of two adult Leydig cell markers.*Hsd3b1*: 3β-hydroxysteroid dehydrogenase; *Insl3*: Insulin-Like 3. Data obtained from our transcriptome analysis.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.011](10.7554/eLife.15635.011)

Consistent with the situation reported for embryonic stages of development ([@bib4]), we observed that the testis phenotype of the different *Sox9/8* compound mutants increased in severity with the number of *Sox9/8* mutant alleles ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}).

[@bib33] reported a *Sox8^-/-^* mouse line in which a progressive deregulation of spermatogenesis occurred and where male mice became sterile by P150. In contrast, our *Sox8* mutants ([@bib49]) do not show such a severe testicular phenotype and males are normally fertile even at P180. At the histological level, our *Sox8^-/-^* mice appeared normal until P120, but showed signs of germ cell desquamation (sloughing) afterwards ([Figure 1---figure supplement 4a--f](#fig1s4){ref-type="fig"}). Genetic background differences between the two *Sox8^-/-^* lines may explain these phenotypic discrepancies. TX-treated controls were similar to untreated males, except between P80 (20 datx) and P120 (60 datx) and mainly at P90 (30 datx), when they showed some degenerating seminiferous tubules, but recovered afterwards ([Figure 1Ca--f](#fig1){ref-type="fig"}, [Figure 1---figure supplement 4a--l](#fig1s4){ref-type="fig"}). Testes in *Sox9/8* DKO (*Sox9*) mice were similar to the TX-treated controls at P70 (10 datx) except for a few testis tubules with enlarged lumen ([Figure 1Cg](#fig1){ref-type="fig"}). At P80 (20datx), only few seminiferous tubules showed signs of degeneration (shrinkage and germ cell depletion), whereas this was more frequent by P90 (30 datx). In many cases, Sertoli cell-only tubules were visible ([Figure 1Ch,i](#fig1){ref-type="fig"}). By P120 (60 datx), tubules had become solid testis cords whose diameter appeared even more reduced at P150 (90 datx) ([Figure 1Cj,k](#fig1){ref-type="fig"}). While some mice continued to exhibit this phenotype at P180 (120 datx), a subset of mice in this group was more affected. In these latter mice Sertoli and germ cells had disappeared completely ([Figure 1Cl](#fig1){ref-type="fig"}). At later time points, all mice showed this severe testicular phenotype. This progressive degeneration of the testicular phenotype in *Sox9/8* SC-DKO mice was evident when we analyzed the relative abundance of the most relevant testicular morphological features between P70 (10 datx) and P180 (120 datx) ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). In contrast, Leydig cells appeared morphologically normal in mutant testes. *Sox9/8* DKO (*Wt1*) mice exhibited a similar testicular phenotype ([Figure 1---figure supplement 4m--r](#fig1s4){ref-type="fig"}). These results show that *Sox8* and *Sox9* alleles act redundantly in adult Sertoli cells and are necessary to maintain the integrity of the seminiferous tubules of functional testes.

Functional status of both somatic and germ cells in testes with *Sox9/8*-deficient Sertoli cells {#s2-2}
------------------------------------------------------------------------------------------------

To better define the mutant phenotype, we next studied the expression of several somatic and germ cell markers. Laminin, a principal component of the basement membrane ([@bib40]) persisted in both P150 (90 datx) and P180 (120 datx) testes of SC-DKO mice ([Figure 1Db,c](#fig1){ref-type="fig"}). *Alpha smooth muscle actin* (*Acta2*) expressed by both peritubular myoid (PM) cells and arterialmuscle fibers was detected in the testes of both TX-treated controls and P150 (90 datx) SC-DKO mice ([Figure 1Dd,e](#fig1){ref-type="fig"}). In contrast, at P180 (120 datx), strong arterial ACTA2 signal persisted but that of PM cells was almost undetectable ([Figure 1Df](#fig1){ref-type="fig"}). This shows that acellular cords in severely affected SC-DKO testes have lost not only Sertoli and germ cells, but also PM cells. Claudin11 is a principal component of tight junctions, the main junctional structures forming the blood-testis barrier (BTB). *Cldn11* (the claudin11 gene) expression was similar between controls and double mutants before P150 (90 datx) (not shown), but it was severely reduced by P150 (90 datx) and completely absent in P180 (120 datx) *Sox9/8* mutant testes ([Figure 1Dg--i](#fig1){ref-type="fig"}), indicating that the BTB is not functional in these testes. To proof this assumption, we tested the permeability of the BTB of P120 (60 datx) mice with a biotin tracer experiment revealing that control testes had a functional BTB, whereas that of the mutant testes had become permeable ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). We also performed immunofluorescence for both PCNA, which is expressed in mitotic spermatogonia as well as in zygotene and early pachytene, but not leptotene spermatocytes ([@bib10]), and DMC1, a meiotic recombination protein marking zygotene-pachytene spermatocytes ([@bib59]). At P60 (30 datx), most mutant seminiferous tubules exhibited a clear reduction of spermatogenic activity and some spermatocytes were abnormally located in the inner region of the tubules ([Figure 1Dk](#fig1){ref-type="fig"}) and not at the periphery, as seen in TX-treated control testes ([Figure 1Dj](#fig1){ref-type="fig"}). In P120 (60 datx) testes, spermatocytes were scarce and only proliferating spermatogonia were seen in most testis tubules (not shown), while at P150 (90 datx), both spermatogonia and spermatocytes had disappeared in most tubules ([Figure 1Dl](#fig1){ref-type="fig"}). These results indicate that spermatogenesis becomes disrupted in testes with Sertoli cells deficient for both *Sox9* and *Sox8*. Unlike other somatic cells, Leydig cells appear not to be seriously affected in testes from *Sox9/8* SC-DKO mice. These cells do not transdifferentiate into theca cells, as they never express *Foxl2* (as theca cells do; not shown), and maintain the steroidogenic function for a long time after *Sox9* ablation, as deduced from the expression of P450scc, a cytochrome involved in the synthesis of testosterone ([Figure 1Dm,n](#fig1){ref-type="fig"}). Consistently, the testosterone-producing enzyme *HSD17b3* and the marker for adult functional Leydig cells *Insl3* are expressed at high levels in the mutant testes ([Figure 1---figure supplement 7](#fig1s7){ref-type="fig"}).

Somatic testis-to-ovary genetic reprogramming in the absence of *Sox9* and *Sox8* in adult mouse testes {#s2-3}
-------------------------------------------------------------------------------------------------------

The loss of *Foxl2* in adult granulosa cells results in a somatic ovary-to-testis genetic reprogramming with granulosa-to-Sertoli cell transdifferentiation which includes *Sox9* upregulation ([@bib54]). Contrarily, *Foxl2* is upregulated when *Sox9* is ablated in embryonic Sertoli cells of *Sox8* null mutants after the sex-determination stage ([@bib19]). To test whether a similar phenomenon took place in our *Sox9/8* SC-DKO mice, we carried out immunofluorescence for FOXL2. At P90 (30 datx), FOXL2 protein was almost completely absent from mutant testes. However, by P105 (45 datx), positive cells were present in almost all testis cords, and by P150 (90 datx), the most severely affected mice showed many FOXL2-positive cells within almost all testis cords ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These results show that transdifferentiation also occurs in adult *Sox9/8* DKO Sertoli cells. Accordingly, we performed a genome-wide transcriptome analysis of P150 untreated control testis, P150 (90 datx) control and mutant testis and control ovary. Our results show that SC-DKO testes exhibit a striking feminization of the testicular transcriptome. [Figure 2B](#fig2){ref-type="fig"} shows a Log~2~-fold-change heat map including the 12,380 genes detected to have significant differential expression between the five sample conditions (the complete list of genes with differential expression is shown in [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}). With the exception of a few gene clusters, most genes in mutant testes adopted an ovary-like expression pattern ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Supplementary file 1](#SD7-data){ref-type="supplementary-material"}). Cluster analyses of all genes, both by replicates and by conditions, showed that mutants are clustered together, with no clear distinction between *Sox9-CreER* and *Wt1-CreER* lines ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Similarly, pairwise gene sets with significant differential expression at α \< 0.05 demonstrated that the number of differentially expressed genes is higher when mutants were compared with testis controls than when compared with ovary ([Figure 2---figure supplement 4A](#fig2s4){ref-type="fig"}). Accordingly, the distance map is higher between mutant and control testis than between mutant testis and ovary ([Figure 2---figure supplement 4B](#fig2s4){ref-type="fig"}). The same results were obtained when comparing isoforms, transcription start sites or coding DNA sequences (not shown). Expression heat maps for selected 39 ovarian somatic cell-specific genes and 33 oocyte-specific genes selected using bioGPS (biogps.gnf.org) revealed that the cell reprogramming observed in the SC-DKO testes only affects somatic cells ([Figure 2C](#fig2){ref-type="fig"}). Notably, bar plots for six genes known to be adult granulosa cell markers showed that these genes were upregulated in the mutant Sertoli cells, revealing an ovary-like expression pattern ([Figure 2D](#fig2){ref-type="fig"}). In addition, within the seminiferous cords of SC-DKO testes we found a few FOXL2^+^ cells expressing the enzyme aromatase ([Figure 2E](#fig2){ref-type="fig"}). This is evidence that, in addition to *Foxl2*, other genes normally expressed by granulosa cells are also transcribed and translated in *Sox9/8* SC-DKO testes.10.7554/eLife.15635.012Figure 2.Genetic reprogramming in somatic cells of adult *Sox9/8* SC-DKO (*Sox9*).(**A**) Expression of FOXL2 (green fluorescence) in P150 (90 datx) TX-treated control (*Sox9^f/f^;Sox8^-/-^*) (a) and in *Sox9/8* SC-DKO (*Sox9*) mouse testes analyzed at P90 (30 datx) (b), P105 (45 datx) (c), and P150 (90 datx) (d) as well as in a P 90 control ovary (e). (**B**) Heatmap showing the 12,380 genes found to be differentially expressed at alpha \< 0.005 when comparing control (*Sox9^f/f^*) and mutant adult gonads. The log~2~(FPKM+1) of each gene in each condition has been divided by the corresponding value in control testis. Gene expression has not been altered by the TX treatment. Red colors indicate genes upregulated with respect to their expression levels in control testis and green colors indicate downregulated genes. (**C**) Expression heatmaps of selected ovarian somatic-specific and oocyte-specific genes. (**D**) Expression bar plots of six relevant ovarian somatic-specific genes upregulated in mutant testes. (**E**) Aromatase (red) and FOXL2 (green) immunofluorescence staining of TX-treated control (*Sox9^f/f^;Sox8^-/-^*) testis (a), mutant testes (b--d), and control ovary (e). Arrows mark reprogrammed Sertoli cells showing simultaneous expression of Aromatase and FOXL2. Scale bar shown in Ae represents 150 µm in **A** and 75 µm in **E**.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.012](10.7554/eLife.15635.012)10.7554/eLife.15635.013Figure 2---source data 1.Genes with significant differential expression among untreated controls, TX-treated controls, *Sox8/9* SC-DKO mutants and control ovary at P150 (90 datx) identified from the bioinformatic analysis of our transcriptome.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.013](10.7554/eLife.15635.013)10.7554/eLife.15635.014Figure 2---figure supplement 1.Expression of *Foxl2* in somatic cells of adult *Sox9/8* DKO (*Wt1*).Immunofluorescence for FOXL2 (green fluorescence) in P150 (90 datx) TX-treated control (*Sox9^f/f^;Sox8^-/-^*) (**a**) and *Sox9/8* DKO (*Wt1*) mouse testes analyzed at P90 (30 datx) (**b**), P105 (45 datx) (**c**), and P150 (90 datx) (**d**) as well as in a control ovary (**e**). Scale bar shown in e represents 150 µm for all the micrographs.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.014](10.7554/eLife.15635.014)10.7554/eLife.15635.015Figure 2---figure supplement 2.Heatmaps showing the expression of genes involved in 8 selected pathways (**A**--**H**), relative to their expression in control testes.Gene sets where obtained from the Pathway Unification Database except for the Myosin genes Family that where obtained from the list of differentially expressed genes. The pathways, URL, and number of genes of each paths are as follow: (**A**) Sertoli-Sertoli Cell Junction Dynamics (<http://pathcards.genecards.org/pathway/543>) 213 genes (**B**) Germ Cell-Sertoli Cell Junction Dynamics (<http://pathcards.genecards.org/pathway/1181>) 140 genes (**C**) Epithelial Tight Junctions (<http://pathcards.genecards.org/pathway/448>) 329 genes (**D**) Regulation of Microtubule Cytoskeleton (<http://pathcards.genecards.org/pathway/792>) 44 genes (**E**) Regulation of actin cytoskeleton SuperPath (<http://pathcards.genecards.org/card/regulation_of_actin_cytoskeleton>) 230 genes (**F**) Myosin Family 26 genes (**G**) Cell-extracellular matrix interactions (<http://pathcards.genecards.org/pathway/286>) 18 genes (**H**) Cell adhesion molecules (<http://pathcards.genecards.org/pathway/1823>) 145 genes The complete lists of genes are included in [Supplementary file 1](#SD7-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.015](10.7554/eLife.15635.015)10.7554/eLife.15635.016Figure 2---figure supplement 3.Cluster analysis of (**A**) replicates and (**B**) conditions.The global gene expression patterns of mutants are closer to the expression in ovaries than to that in normal testes. Both controls with and without Tamoxifen treatment also group together as expected.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.016](10.7554/eLife.15635.016)10.7554/eLife.15635.017Figure 2---figure supplement 4.Quantification of genes with differential expression and Jensen--Shannon (JS) distances between conditions.(**A**) Number of genes showing differential expression in pairwise comparisons of the different conditions.(**B**) Jensen--Shannon (JS) distances heatmap between conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.017](10.7554/eLife.15635.017)

Sertoli-to-granulosa cell transdifferentiation in adult *Sox9/8* SC-DKO testes {#s2-4}
------------------------------------------------------------------------------

We next investigated the origin of the granulosa-like, FOXL2^+^ cells present in the *Sox9/8* SC-DKO testes. Several pieces of evidence show that FOXL2^+^ cells in our mutant testes originate from *Sox9/8* null Sertoli cells. The two gene promoters we used to drive *Cre* expression (*Sox9* and *Wt1*) are Sertoli cell-specific in the testis, indicating that transdifferentiation originates directly from this cell type. Importantly, we found that FOXL2^+^ cells always located inside testis cords with strong expression of the Cre-recombination reporter EYFP ([Figure 3A](#fig3){ref-type="fig"}). We also analyzed the expression of WT1, a Sertoli cell marker whose expression is maintained after *Sox9/8* ablation in embryonic mouse Sertoli cells ([@bib4]), and that it is co-expressed with FOXL2 in granulosa cells of immature, but not mature, follicles ([@bib12]; [Figure 3Ce](#fig3){ref-type="fig"}). At P90 (30 datx) we observed many WT1^+^ Sertoli cells that have already lost SOX9 (green cells, [Figure 3Bb](#fig3){ref-type="fig"}). The number of WT1^+^ SOX9^-^ cells decreased by P150 (90 datx) [(Figure 3Bc](#fig3){ref-type="fig"}), indicating that recombined Sertoli cells were being lost. This decrease in the number of WT1^+^ SOX9^-^ Sertoli cells coincides with an increase in the number of FOXL2^+^ cells which either retain weak WT1-staining or are WT1^-^ ([Figure 3C](#fig3){ref-type="fig"}), suggesting that FOXL2^+^ cells originate from cells previously expressing WT1, that is Sertoli cells. Altogether, these results indicate that *Sox9/8* SC-DKO testes experience a cell-autonomous Sertoli-to-granulosa cell transdifferentiation which triggers the observed testis-to-ovary genetic reprogramming in these gonads.10.7554/eLife.15635.018Figure 3.Identification of the somatic cells expressing FOXL2.(**A**) Double immunofluorescence for FOXL2 (green, nuclear) and EYFP (red, cytoplasmic) (**B**) Double immunofluorescence for SOX9 and WT1 in P150 (90 datx) TX-treated control (*Sox9^f/f^;Sox8^-/-^*) testes (a) and *Sox9/8* SC-DKO testes analyzed at P90 (30 datx) (b) and P150 (90 datx) (c). Dashed lines delineate the seminiferous tubules contour. Arrows mark mutant cells expressing WT1 but not SOX9. (**C**) Double immunofluorescence for FOXL2 and WT1 in both TX-treated control (*Sox9^f/f^;Sox8^-/-^*) (a) and *Sox9/8* SC-DKO mutant testes analyzed at P120 (60 datx) (b--d), as well as in a control ovary (e). Arrows point to mutant cells expressing both proteins. Scale bar in **Ac** represents 25 μm in **A**; scale bar in **Bc** represents 25 μm in **B**; scale bar in **Cd** represents 25 μm in **Ca--d** and scale bar in **Ce** represents 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.018](10.7554/eLife.15635.018)

Sertoli-to-granulosa cell transdifferentiation is mediated by *Dmrt1* downregulation in *Sox9/8* SC-DKO testes {#s2-5}
--------------------------------------------------------------------------------------------------------------

Since *Sox9* is upregulated after *Foxl2* ablation in adult granulosa cells ([@bib54]) and downregulated after *Dmrt1* ablation in embryonic Sertoli cells ([@bib28]), we investigated the expression pattern of these two genes in the testes of the *Sox9/8* SC-DKO mutants. We found that cells coexpressing SOX9 and FOXL2 were rare at any stage analyzed \[12 out of 203 FOXL2^+^ cells co-expressed SOX9 at P120 (60 datx)\] ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), indicating that *Foxl2* upregulation requires previous elimination of both SOXE proteins. Next, we examined the expression of both *Sox9* and *Dmrt1* in *Sox9/8* SC-DKO testes. As *Dmrt1* is expressed in both Sertoli cells and spermatogonia of adult testes ([@bib38]), we used a third marker, PCNA, that labels spermatogonia as well as zygotene and early pachytene spermatocytes. Whereas all Sertoli cells in control testes showed strong staining for both DMRT1 and SOX9 (SS, [Figure 4Ba](#fig4){ref-type="fig"}), mutant Sertoli cells showed varying degrees of both SOX9 and DMRT1 staining intensity, although they normally paralleled each other in intensity. Therefore Sertoli cells with a weak staining for both DMRT1 and SOX9 (WS) were also visible in these testes. Consistent with this, we found a very reduced number of cells expressing only DMRT1 at P90 (30 datx) ([Figure 4Bb--d](#fig4){ref-type="fig"}, red cells (arrow); SOX9^-^ DMRT1^+^ PCNA^-^) and almost none at P120 (60 datx) ([Figure 4Be--g](#fig4){ref-type="fig"}). Furthermore, in P150 (90 datx) testes, which are almost devoid of germ cells, DMRT1 immunoreactivity was almost exclusively restricted to SOX9^+^ cells ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Double WT1-DMRT1 staining confirmed that as early as at P90 (30 datx) many WT1^+^ cells (Sertoli cells) have already lost DMRT1 expression (green cells in [Figure 4Cb](#fig4){ref-type="fig"}), showing that *Dmrt1* is downregulated after *Sox9* ablation and before *Wt1* downregulation occurs in SC-DKO testes. In addition, as observed for SOX9 and FOXL2 (see above), DMRT1 and FOXL2 only colocalize in a reduced number of cells in the testes of our *Sox9/8* SC-DKO mice \[16 out of 127 FOXL2^+^ cells co-expressed DMRT1 at P120 (60 datx)\] ([Figure 4D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Overall, these findings support the notion that SOX9 and SOX8 are necessary for the maintenance of *Dmrt1* expression in adult Sertoli cells and that these testis-promoting factors negatively regulate *Foxl2*.10.7554/eLife.15635.019Figure 4.Role of *Dmrt1* in Sertoli-to-granulosa cell transdifferentiation.(**A**) Double immunofluorescence for SOX9 and FOXL2 in TX-treated control (*Sox9^f/f^;Sox8^-/-^*) testis (a), *Sox9/8* SC-DKO mutant testes analyzed at P105 (45 datx) and P150 (90 datx) (b,c) and a control ovary (d) (b\' is a higher magnification of the area marked in b). Colocalization of SOX9 and FOXL2 was rare and the few observed cells showed weak fluorescence for both proteins (arrowheads in b\'). (**B**) Triple immunofluorescence for SOX9, DMRT1 and PCNA (germ cell marker) in P150 (90 datx) TX-treated control (*Sox9^f/f^;Sox8^-/-^*) testes (a) and *Sox9/8* SC-DKO mutant testes at P90 (30 datx) (b--d) and P120 (60 datx) (e-g). Different cell types can be identified: SS: Sertoli cells with strong staining for both DMRT1 and SOX9 (SOX9^+^ DMRT1^+^ PCNA^-^; strong yellow); WS: Sertoli cells with weak staining for both DMRT1 and SOX9 (SOX9^+^ DMRT1^+^ PCNA^-^; pale yellow); SP: spermatocytes (SOX9^-^ DMRT1^-^ PCNA^+^; blue); SG: proliferating spermatogonia (SOX9^-^ DMRT1^+^ PCNA^+^; purple), arrow (SOX9^-^ DMRT1^+^ PCNA^-^; red). Non-proliferating spermatogonia could be confused in *Sox9/8* SC-DKO mice with recombined DMRT1^+^ SOX9^-^ Sertoli cells in which SOX9 already disappeared, but the number of the former cell type is so low that they can be ignored. (**C**) Double immunofluorescence for DMRT1 and WT1 in P90 (30 datx) TX-treated control (*Sox9^f/f^;Sox8^-/-^*) (a) and mutant testes (b). (**D**) Double immunofluorescence for DMRT1 and FOXL2 in P150 (90 datx) TX-treated control (*Sox9^f/f^;Sox8^-/-^*) testis (a), *Sox9/8* SC-DKO mutant testes (b--c) and control ovary (d) (b\' is a higher magnification of the area marked in b). Colocalization of both proteins was rare (arrowheads in b\'). Scale bar in **Dd** represent 50 µm in **A** and **D**; scale bar in **Bg** represents 25 µm in **B**; scale bar in **Cb** represents 50 µm in **C**.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.019](10.7554/eLife.15635.019)10.7554/eLife.15635.020Figure 4---figure supplement 1.Role of Dmrt1 in Sertoli-to-granulosa cell transdifferentiation.Double immunofluorescence for SOX9 and FOXL2 (**A**), and for FOXL2 and DMRT1 (**C**) as shown in [Figure 4](#fig4){ref-type="fig"} but showing separated the single color channels (a\', c\' and e\' are higher magnifications of the areas marked in a, c and e in both **A** and **C**). Triple immunofluorescence for SOX9, DMRT1 and PCNA (**B**) of P150 (90 datx) *Sox9/8* DKO (*Sox9*) testis. Arrowheads in **A** and **C** indicate colocalization of both proteins. Scale bar in **Cf** represent 50 μm in **A** and **C**; scale bar in **Bc** represents 25 μm in **B**.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.020](10.7554/eLife.15635.020)

To further test this hypothesis, we compared the microarray data from P28 SC*-Dmrt1* KO testes reported by [@bib29] with the RNA-seq data from our P150 (90 datx) SC*-Sox9/8* DKO testes, and plotted all mRNAs that resulted either downregulated or upregulated when compared to control males in both datasets ([Figure 5A](#fig5){ref-type="fig"}, small blue dots). Nearly all genes strongly affected by the loss of *Dmrt1* were also affected by the loss of *Sox9/8* ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---source data 1](#SD3-data){ref-type="supplementary-material"}). This finding suggests that both *Dmrt1* and *Sox9/8* act in the same pathway, although the possibility also exists that this coincidence between both gene expression patterns could be a secondary effect of the change in relative numbers of cell types in the SC-*Sox9/8* DKO testes. Among the genes upregulated in both experiments (upper right quadrant in [Figure 5A](#fig5){ref-type="fig"}), we found 29 somatic ovarian-specific genes including female promoting genes such as *Foxl2, Wnt4, Rspo1, Fst, Fshr* ([Figure 5A](#fig5){ref-type="fig"}, red triangles). Also, a set of genes were upregulated in *Dmrt1* mutants and downregulated in *Sox9/8* mutants (upper-left quadrant in [Figure 5A](#fig5){ref-type="fig"}), which may be a consequence of 1) the age-differences between the two compared sample sets, 2) the incomplete efficiency of *Sox9* inactivation of our conditional SC*-Sox9* KO, or 3) the existence of additional roles for *Sox9/8* and/or *Dmrt1* in the adult testis.10.7554/eLife.15635.021Figure 5.*Sox9* and *Dmrt1* act in the same pathway during Sertoli-to-granulosa transdifferentiation.(**A**) Log~2~ fold change scatterplot comparing the microarray data from the P28 SC-*Dmrt1* KO testes reported by [@bib29]; GEO accession: GSE27261) with the RNA-seq data from our P150 (90 datx) *SC-Sox9/8* DKO testes, including 8910 genes showing significant differential expression respect to normal testis in both *Dmrt1* and *Sox9/8* mutants (blue dots). Among these, green dots represent 24 genes belonging to the all-trans-retinoic acid-mediated apoptosis path and RA receptors-mediated signaling from the PathCards database. Red triangle show 29 of the ovarian somatic specific genes included in [Figure 2C](#fig2){ref-type="fig"}. The names of some relevant genes are indicated. Regression line is shown in red (intecept = 0.7112, slope = 1.0883). (**B**) Effect of the treatment of *Sox9/8* SC-DKO mice with WIN 18,644 on Sertoli-to-granulosa cell transdifferentiation. FOXL2-positive cells (green fluorescence) were much more abundant in untreated (**a**) than in treated mutant testes (**b**). The number of positive cells per testis/cord section was 3.5-fold higher in untreated mice (**c**). The ACTA2 signal (red fluorescence) permitted to delineate the testis cords in a and b. Scale bar in **Bb** represents 100 µm in **Ba**--**b**.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.021](10.7554/eLife.15635.021)10.7554/eLife.15635.022Figure 5---source data 1.List of 8910 genes showing significant differential expression respect to normal testis in both *Dmrt1* and *Sox9/8* mutants.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.022](10.7554/eLife.15635.022)10.7554/eLife.15635.023Figure 5---source data 2.Log~2~ fold change of expression of both *Dmrt1* and *Sox9/8* mutants respect to controls in a set of genes belonging to the all-trans-retinoic acid-mediated apoptosis path and RA receptors-mediated signaling from the PathCards database.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.023](10.7554/eLife.15635.023)10.7554/eLife.15635.024Figure 5---source data 3.Comparison of the number of FOXL2^+^ cells per transversal testis cord section in *Sox9/8* DKO (*Sox9*) WIN 18,446-treated mice and vehicle-injected controls**DOI:** [http://dx.doi.org/10.7554/eLife.15635.024](10.7554/eLife.15635.024)

It was recently reported ([@bib32]) that DMRT1 functions by protecting male gonadal cells from retinoid acid (RA)-dependent sexual transdifferentiation and that this process could be inhibited by blocking intra-tubular RA synthesis in the *Dmrt1*-mutant testes. By comparing the mRNA profiling of SC-*Dmrt1* KO and *SC-Sox9/8* DKO testes, we found a set of genes belonging to the RA-signaling pathway showing similar misexpression in both mutants ([Figure 5A](#fig5){ref-type="fig"}, green dots, [Figure 5---source data 2](#SD4-data){ref-type="supplementary-material"}). As *Dmrt1* is downregulated in the *Sox9/8* SC-DKO testes, we hypothesized that reducing RA levels in our *SoxE* mutants should also affect the transdifferentiation process. To test this, we treated adult SC-DKO mice with the retinaldehyde dehydrogenase inhibitor WIN 18,446 just when the first FOXL2-positive cells are detected. We found a 3.5-fold reduction in the number of FOXL2-positive cells per testis cord section in the WIN 18,446-treated mice (1.80 ± 2.03), compared to the vehicle (DMSO)-injected controls (6.57 ± 3.52; p\<0.001; [Figure 5B](#fig5){ref-type="fig"}, [Figure 5---source data 3](#SD5-data){ref-type="supplementary-material"}). Hence, as reported for *Dmrt1* SC-KO mice ([@bib32]), the process of Sertoli-to-granulosa cell transdifferentiation seems to be also inhibited when RA levels were reduced in our study model.

SOX9 and SOX8 act as anti-apoptotic factors in adult Sertoli cells {#s2-6}
------------------------------------------------------------------

Coinciding roughly with the end of TX treatment, *Sox9/8* SC-DKO testes begin to progressively degenerate, as evidenced by shrinkage of the seminiferous tubules, which in the most severely affected mice reach an extreme degree of tubular involution and become acellular testis cords. A possible explanation for the loss of tubular somatic cells is that apoptosis is operating in these testes. TUNEL assay revealed apoptotic cells mainly inside the testis tubules/cords, showing that interstitial cells (mostly Leydig cells) are not seriously affected. The numbers of TUNEL-positive cells counted in a total area of 11.55 mm^2^ between P90 (30 datx) and P120 (60 datx) in both SC-DKO mutants (370 cells for the *Wt1-CreERT2* line and 488 cells for the *Sox9-CreERT2* line) were significantly higher than those found in TX-treated control testes (120 cells; goodness of fit test p\<2.2e-16 in both cases; [Figure 6Aa--c](#fig6){ref-type="fig"}, [Figure 6---source data 1](#SD6-data){ref-type="supplementary-material"}). The presence of abundant apoptotic bodies at P150 (90 datx) ([Figure 6Ad](#fig6){ref-type="fig"}) documents the massive cell death that had occurred during previous stages in the *Sox9/8* SC-DKO mice.10.7554/eLife.15635.025Figure 6.Incidence of apoptosis in *Sox9/8* SC-DKO testes.(**A**) TUNEL staining in testis sections of TX-treated control (*Sox9^f/f^;Sox8^-/-^*) at P120 (60 datx) (a) and *Sox9/8* SC-DKO at different time-points (b--d). (**B**) Double immunofluorescence for TUNEL and three molecular markers: SOX9 \[a, (P90 (30datx)) and b, (P150 (90 datx))\], FOXL2 (c, P120 (60 datx)), and WT1 (d, P90 (30 datx)). Arrows in b and d mark cells showing coexpression of the two proteins. Scale bar in Ac represents 100 µm for **Aa**--**c**; scale bar in **Ad** represents 50 µm; scale bar in **Bd** represents 50 µm in **B**.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.025](10.7554/eLife.15635.025)10.7554/eLife.15635.026Figure 6---source data 1.Comparison of the number of TUNEL-positive cells per section area unit in both SC-DKO mutants and TX-treated controls.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.026](10.7554/eLife.15635.026)

To identify the cell types undergoing apoptosis, we combined TUNEL staining with immunofluorescence for several molecular markers. Neither SOX9- nor FOXL2-expressing cells were observed to be apoptotic in mutant testes before P120 (60 datx) ([Figure 6Ba,c](#fig6){ref-type="fig"}), but SOX9^+^ cells were found to be apoptotic in the P150 (90 datx) testes ([Figure 6Bb](#fig6){ref-type="fig"}). In contrast, we observed apoptotic cells expressing WT1 as early as P90 (30 datx) ([Figure 6Bd](#fig6){ref-type="fig"}), indicating that apoptosis mainly affects recombined Sertoli cells in which *Sox9* had been ablated but *Foxl2* had not yet been upregulated. Altogether, these findings suggest that testis regression in *Sox9/8* mutants occurs in two different stages. During the first two months after the initiation of TX administration, both non-recombined Sertoli cells (SOX9^+^) and transdifferentiated cells (FOXL2^+^) remain alive, whereas recombined but not yet transdifferentiated cells (SOX9^−^ , WT1^+^) do undergo apoptosis. In the second stage (P180 and older mice), massive apoptosis affects all cell types, including the remaining Sertoli cells and granulosa-like cells.

Discussion {#s3}
==========

The battle of sexes persists beyond the sex determination stage {#s3-1}
---------------------------------------------------------------

There is now compelling evidence that the bipotential nature of the genital ridge at the beginning of gonad development is not completely lost once either testes or ovaries acquire their final adult morphology and functionality. During embryonic development the newly formed Sertoli cells can transdifferentiate to their ovarian counterparts when the testis promoting factors *Sox9* or *Dmrt1* are lost ([@bib19]; [@bib28]). The finding that *Foxl2* in the adult ovary was necessary to prevent granulosa-to-Sertoli cell transdifferentation revealed that this antagonism also operates in the adult gonad. In the adult testis, the same antagonism also appears to exist, as FOXL2^+^ cells were observed when *Dmrt1* was ubiquitously deleted ([@bib28]). Here we show that Sertoli-to-granulosa cell transdifferentiation can be induced as well in the adult mouse testis by just deleting two *SoxE* genes*, Sox9 and Sox8.* These results evidence that *Sox9* has a crucial role, not only during sex determination and testis differentiation, but also in adult testis maintenance, where, together with *Sox8* and coordinately with *Dmrt1,* it prevents male-to-female genetic reprogramming.

The regulatory relationship between *Dmrt1* and *Sox9* requires further discussion. At the sex determination stage of the mouse (E11.5), both *Sox9* and *Dmrt1* are expressed in the early embryonic testis ([@bib20]; [@bib37]), but whereas early embryonic *Sox9* mutants show sex reversal ([@bib8]; [@bib2]), early embryonic *Dmrt1* KO mice have testes that express *Sox9* and appear histologically normal until P7 ([@bib38]). Thus, *Sox9* expression is independent of DMRT1 during sex determination and some time thereafter. Similarly, Sertoli cell-specific inactivation of *Sox9/8* at E13.5, shortly after the sex determination stage, leads to a rapid downregulation of *Dmrt1* that becomes already visible four days later, at E17.5 ([@bib19]). In contrast, *Dmrt1* ablation at E13.5 results in a very delayed *Sox9* downregulation, which is seen at P14 (one month later), coinciding with *Foxl2* upregulation ([@bib28]). This suggests again that *Sox9* expression is independent of *Dmrt1* in newly differentiated Sertoli cells and that the loss of *Sox9* after *Dmrt1* ablation is a secondary consequence of the upregulation of ovarian genes(s), such as *Foxl2*, in the same cells. On the other hand, several observations suggest the transactivation of *SOX9* by DMRT1: 1) DMRT1 binds near the *Sox9* locus in P28 mouse testes ([@bib28]), 2) ectopic expression of *Dmrt1* in embryonic XX gonads causes XX sex reversal with upregulation of *Sox9* ([@bib60]) and 3) *FOXL2^-/-^* sex reversed polled goats undergo a process of transdifferentiation in which *DMRT1* expression precedes the upregulation of *SOX9* ([@bib15]). In the latter two cases, however, female-promoting genes, including *FOXL2*, are either downregulated or not expressed, and thus, *SOX9* upregulation could be again an indirect consequence of the downregulation of female-promoting genes. Here we provide evidence that in the adult gonad, mutant *Sox9/8* Sertoli cells lose DMRT1, and that FOXL2 protein appears concomitant with the loss of DMRT1, consistent with the notion that *Dmrt1* expression is SOX9/8-dependent and that DMTR1 represses *Foxl2*. Additional observations support this view: 1) nearly all the genes strongly affected by the loss of DMRT1 were also affected by the loss of SOX9/8; 2) Sertoli-to-granulosa cell transdifferentiation observed in the testes of our *Sox9/8* mutant mice may be reduced by decreasing levels of RA, a signaling pathway known to be blocked by DMRT1 in Sertoli cells to prevent *Foxl2* expression and transdifferentiation into granulosa-like cells ([@bib32]); 3) DMRT1 can silence *Foxl2* in the absence of SOX9 and SOX8 ([@bib25]); and 4) *Sox9* is upregulated in the adult ovary after the ectopic expression of *Dmrt1*, coinciding with *Foxl2* downregulation ([@bib25]). Altogether, available data suggest that, like at earlier stages, a main role for SOX9/8 in adult male sex maintenance is to keep *Dmrt1* actively expressed, this latter gene having a fundamental role in repressing female-specific genes. However, these observations do not rule out the possibility that DMRT1 is also necessary for the maintenance of *Sox9* expression in the adult testis and that a feed-forward regulatory loop between *Sox9/8* and *Dmrt1* exists that ensures testis maintenance and antagonizes the feminizing action of *Foxl2*. Additional experiments (e.g. a time course of *Sox9* expression in adult SC-DKO *Dmrt1* mice) will help to clarify this issue.

There is evidence that *Wt1* acts upstream of both *Sox9* and *Sox8* during the early stages of embryonic testis development ([@bib18]; [@bib4]). In the adult testis, we have seen that *Sox9/8*-depleted Sertoli cells initially maintain WT1 expression, but this expression becomes progressively downregulated coinciding with the time-point at which *Foxl2* is upregulated. This suggests that *Wt1* retains its hierarchical position also in the adult testis, and that female-specific factors, including *Foxl2,* may be involved in its silencing. Consistent with previous studies ([@bib12]; [@bib44]), we detected two types of granulosa cells in the normal adult ovary ([Figure 3Ce](#fig3){ref-type="fig"}): 1) those located in antral (mature) follicles express FOXL2 but not WT1, and 2) those located in pre-antral follicles express both proteins. Thus, considering these two molecular markers, transdifferentiation of *Sox9/8* SC-DKO Sertoli cells seems to give rise to mature follicle-type granulosa cells. This expression pattern also suggests that WT1 may play an anti-feminizing role in adult Sertoli cells.

SOX9 and SOX8 are necessary to maintain tubular architecture and function in adult testes {#s3-2}
-----------------------------------------------------------------------------------------

We have reported here that the functional redundancy between the *Sox9* and *Sox8* alleles observed in embryonic Sertoli cells ([@bib4]) and other embryonic cell types ([@bib8]; [@bib51]; [@bib39]) is also maintained in adult Sertoli cells. The phenotype of mutant testes becomes ever more severe as the numbers of null alleles increase in their genotype, with extreme phenotypes observed in homozygous DKO testes 4 months after the beginning of TX treatment, at which stage seminiferous tubules have literally disappeared. As Sertoli cell proliferation stops once they obtain their adult appearance ([@bib22]), programmed cell death in *Sox9/8* mutants may explain their reduction in number. Consistently, we found no SOX9^+^ apoptotic cell by P90 (30 datx), indicating that *Sox9/8* initially protects Sertoli cells from apoptosis, a role previously shown for this gene in other developing organs ([@bib1]; [@bib11]; [@bib47]). Similarly, newly differentiated FOXL2^+^ cells did also not apoptose, showing that reprogrammed granulosa-like cells are also protected from apoptosis. However, the situation was substantially different in P150 (90 datx) mutant testes, where apoptosis was intense. At these late stages of testis regression, cord structure was dramatically compromised and even Sertoli cells still expressing *Sox9* were seen to undergo apoptosis. It is well known that the number of Sertoli cells must reach a critical threshold to organize embryonic testicular cords ([@bib34]; [@bib43]). Accordingly, our results suggest that adult testis tubules also require the presence of a minimum number of Sertoli cells to be maintained. The progressive loss of Sertoli cells after *Sox9/8* ablation, either by apoptosis or by transdifferentiation into granulosa-like cells, appears to reach a point of no return at which the remaining normal Sertoli cells are unable to support the tubular structure and are also induced to apoptose. Hence, our results show that SOXE factors are necessary to maintain Sertoli cell identity and seminiferous tubule integrity, as these cells maintain all the other cell types forming the tubules, which become completely disorganized in their absence.

Several findings suggest that deregulation of important structural proteins controlled by *SoxE* genes could be involved in the process. SOX9 controls, either directly ([@bib5]) or indirectly ([@bib3]; [@bib19]), the expression of extracellular matrix proteins, which contribute importantly to the tubular structure. *Sox8^-/-^* mice show increased BTB permeability and greatly reduced levels of α-tubulin acetylation, suggesting that impairment of the Sertoli cell cytoskeleton may have modified the microenvironment of the seminiferous epithelium ([@bib48]). Also, after *Sox9* ablation in *Sox8* mutants, both developing ([@bib4]; [@bib19]) and adult testes (present paper) experience downregulation and/or abnormal distribution of several important proteins required for the formation of Sertoli--Sertoli and/or Sertoli--germ cell adhesion complexes ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). In this context, it is noteworthy that spermatogenesis is halted when the functionality of the BTB is impaired ([@bib30]; [@bib14]). Thus, in our *Sox9/8* SC-DKO mouse testes, BTB permeation and cytoskeleton impairment may give rise to a damaged intra-tubular microenvironment in which spermatogenesis is not supported anymore, germ cells undergoing both apoptosis and desquamation. Altogether, available data strongly suggest that failure of *Sox9/8* double mutant Sertoli cells to sustain testis tubule architecture is a direct consequence of altered expression of cell adhesion molecules and probably of other structural elements such as components of the cytoskeleton or the extracellular matrix.

Regarding the somatic cells of the testis, PM cells disappear in *Sox9/8* mutant testes, whereas Leydig cells appear not to be affected, as they express the Leydig cell markers *HSD17b3* and *Insl3*. Although PM and Leydig cell specification is induced by Sertoli cells during early testis development (reviewed by [@bib52]), at later stages of testis development (E14.5 and onward) Leydig cells do not require Sertoli cells for proliferation and synthesis of testosterone ([@bib18]). Our results in the adult testis show that adult PM cells retain their original dependence from Sertoli cells, whereas maintenance of adult Leydig cells is again Sertoli cell-independent. Further research is required to unravel the actual functional status of Leydig cells in *Sox9/8* mutant testes.

A regulatory model for adult testis maintenance in mice {#s3-3}
-------------------------------------------------------

According to the above considerations, we propose a model for the maintenance of Sertoli cell fate in the adult testis. In this model*, Sox9/8* play a central role in maintaining active *Dmrt1,* which prevents expression of ovary promoting genes, including *Foxl2,* which in turn negatively regulates *Sox9/8* and/or *Dmrt1. Dmrt1* inhibits RA signaling which promotes the expression of *Foxl2,* although an interference of *Sox9* on this signaling pathway, through a *Dmrt1*-independent mechanism, cannot be ruled out. Wt1 positively regulates *Sox8/9* and is negatively regulated by *Foxl2* and/or other ovarian-specific genes. *Sox9/8* are also needed for maintaining the expression of important testis structural genes and for protecting Sertoli cells from apoptosis ([Figure 7](#fig7){ref-type="fig"}, solid lines). It is also possible that *Dmrt1* may establish feed-forward regulatory loop with *Sox9/8* and that *Sox9/8* repress the expression of ovary-specific mRNAs through *Dmrt1*-independent mechanisms, although these interactions are less strongly supported by available data ([Figure 7](#fig7){ref-type="fig"}, dashed lines).10.7554/eLife.15635.027Figure 7.Model for the regulation of mammalian sex maintenance.Positive regulation is indicated by arrows. Negative regulation is indicated by perpendicular lines. See text for a detailed explanation.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.027](10.7554/eLife.15635.027)

In conclusion, we have shown *Sox9/8* have important DMRT1*-*dependent and independent functions in the maintenance of the adult testis. In their absence, phenotypically normal, fertile testes are genetically reprogrammed and Sertoli-to-granulosa cell transdifferentiation occurs. Nevertheless, this is a mere transient stage of mutant adult Sertoli cells in the irreversible degenerative process the seminiferous tubules face in the absence of *Sox9* and *Sox8*.

Material and methods {#s4}
====================

Mouse lines and crosses {#s4-1}
-----------------------

Previously generated *Sox9^f/f^; Sox8^-/-^*mice ([@bib4]; [@bib21]; [@bib49]) were bred to *Wt1-CreERT2* mice ([@bib61]) and the resulting double heterozygous offspring harboring the *Cre* allele was backcrossed to *Sox9^f/f^; Sox8^-/- ^*mice to obtain heterozygous and homozygous compound *Sox9; Sox8* conditional mutants. The same mating scheme was followed with the *Sox9-CreERT2* mouse line ([@bib23]). To report CRE activity, the R26R-EYFP reporter allele ([@bib50]) was crossed into *Wt1-CreERT2; Sox9^f/f^; Sox8^-/-^ and Sox9-CreERT2; Sox9^f/f^; Sox8^-/- ^*mice. For genotyping we performed PCR and qPCR with DNA purified from tail tips. Primers and PCR conditions for Sox9*^flox^, Sox8^-^, Cre,* and *R26R-EYFP* were used as described [@bib4]. Mouse housing and handling, as well as laboratory protocols, were approved by the University of Granada Ethics Committee for Animal Experimentation.

Tamoxifen administration {#s4-2}
------------------------

Tamoxifen (Sigma, T5648) dissolved in corn oil (Sigma, C8267) at a concentration of 30 mg/ml and 0.16 mg of TX per gram of body weight was initially administered orally to mice with a feeding needle for 5 consecutive days. With this treatment *Sox9/8* double mutants displayed a 90% lethality, so we reduced the dose of TX (down to 0.07 mg TX / gr of body weight) and 90% of *Sox9/8* double mutants survived, but the efficiency of CRE recombination fell then to below 20%. Then, we tried to feed mice with a TX-supplemented diet (40 mg TX/100 g Harlan 2914 diet) for one month. This treatment resulted in a 100% survival rate. TX administrations were started at 2 months (P60) and finished 30 days after the beginning of TX administration (P90 \[30 datx\]) ([Figure 1A](#fig1){ref-type="fig"}). All results presented here, except those included in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}, were obtained from mice fed with the TX-supplemented diet.

Histological and immunostaining methods {#s4-3}
---------------------------------------

Gonads were dissected out, weighted and prepared for standard histological methods, including haematoxylin and eosin staining. Single and multiple immunofluorescence were performed as previously described ([@bib14]). [Table 1](#tbl1){ref-type="table"} summarizes the antibodies used.10.7554/eLife.15635.028Table 1.Antibodies used in this study.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.028](10.7554/eLife.15635.028)Gene productRaised inWorking dilutionReferencesLamininrabbit1:100Sigma L9393ACTA2mouse1:200Sigma A2547Claudin11rabbit1:100Santa Cruz Biotechnology, CA sc-25711DMC1goat1:100Santa Cruz Biotechnology, CA sc-8973PCNAmouse1:100Santa Cruz Biotechnology, CA sc-56CYP14A1 (P450scc)goat1:200Santa Cruz Biotechnology, CA sc-18043SOX9rabbit1:100Santa Cruz Biotechnology, CA sc-20095SOX9goat1:10Santa Cruz Biotechnology, CA sc-17341WT1rabbit1:100Santa Cruz Biotechnology, CA sc-192FOXL2goat1:100Abcam ab5096GFPrabbit1:100Novus Biologicals NB600-308WT1mouse1:30DAKO M3561 (clone 6F-H2)CYP19A1 (Aromatase)mouse1:10GeneTex GTX41561DMRT1rabbit1:400Gift from Dr. Silvana Guioli

Analysis of apoptosis {#s4-4}
---------------------

To perform the TUNEL technique we used the Fluorescent In Situ Cell Death Detection Kit (Roche, Mannheim, Germany) according to the manufacturer\'s instruction.

Analysis of BTB Permeability {#s4-5}
----------------------------

The in vivo test to analyze the permeability of the BTB in the testes of control and mutant mice was performed using a biotin-labelled tracer compound (EZ-Link Sulfo-NHS-LC-Biotin tracer, Thermo Scientific) as described ([@bib14]).

WIN 18,446 treatment {#s4-6}
--------------------

TX-treated *Sox9-CreERT2; Sox9^f/f^; Sox8^-/-^*mice were injected subcutaneously either with 40 μg/μl WIN 18,446 (Tocris, Biotechne, UK, Cat. No 4736), dissolved in 50 μl dimethyl sulfoxide or with the vehicle alone for 8 days, 4 days before and 4 days after the end of the 30 days diet TX treatment. Fifteen days after the end of WIN 18,446 treatment, gonads were collected and processed for double immunofluorescense for ACTA2 and FOXL2 as described above. The number of FOXL2^+^ cells per transversal ST section was counted in 20 tubules of 5 WIN 18,446-treated and 5 control animals. Only circular or ellipsoid tubular sections in which the major/minor axis ratio was lower than two were used for counts.

Transcriptome analysis {#s4-7}
----------------------

Both testes were extracted from six P150 (90 datx) mutant males (three *Wt1-CreERT2; Sox9^f/f^; Sox8^-/-^*and three *Sox9-CreERT2; Sox9^f/f^; Sox8^-/-^*). As controls, both gonads were also extracted from two P150 (not treated) and two P150 (90 datx) *Sox9^f/f^* male mice as well as from two 4--5 months old normal females. All TX-treated mice were euthanized three months after the initiation of diet TX-treatment for one month. The two gonads of each individual were pooled, homogenized in 1 ml of RNAzol (Molecular Research Center, Inc.) per 100 mg of tissue and the total RNAs were then individually purified from the twelve samples following the RNAzol manufacturer's instructions. After successfully passing Macrogen Inc. quality check, the twelve RNAs were paired-end sequenced separately in an Illumina HiSeq 2000 platform at that company and the quality of the resulting sequencing reads was assessed using FastQC (<http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/>).

Bioinformatics {#s4-8}
--------------

RNAseq data were processed with the Tuxedo tools ([@bib53]). Alignments were done with Tophat/Bowtie2 against the mm10 UCSC annotated mouse genome. Differential expression analyses where done with Cuffdiff. Analysis of the resulting data were performed with the CummeRbund Bioconductor package. The quality of RNA-seq was checked as described in the package documentation. Briefly, by comparing FPKM scores across samples, and looking for outliers replicates, by analyzing squared coefficient of variation which allows visualization of cross-replicate variability between conditions and by analyzing the dispersion plots ([Figure 8](#fig8){ref-type="fig"}).10.7554/eLife.15635.029Figure 8.Pairwise scatterplots comparing log~10~ FPKM between different conditions.Dispersion is lower when comparing similar conditions (controls, mutants) and higher when comparing mutant with control conditions. Notice that dispersion observed when mutants are compared with ovary is lower than that observed comparing them with any of the testis controls.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.029](10.7554/eLife.15635.029)

To explain the presence of both *Sox9* and *Sox8* transcripts in the transcriptome of double homozygotes for the null allele, their transcripts where visualised with the IGV genome browser ([@bib42]). Recombinant *Sox9* locus is seen by Cuffkinks and IGV as an alternative spliced transcript. Sashimi plots show that the CRE recombination is not 100% effective as transcripts with the correct splicing still remain in both mutant conditions but a high proportion of the *Sox9* genes are efficiently deleted. These plots also show that in the absence of the 2nd and 3rd exons after recombination, alternative intron donor and acceptor sites downstream of *Sox9* can be used for splicing. *Sox8* transcripts only include the 5' untranslated portion of the transcripts demonstrating that these individuals are actually Sox8^−/−^ ([Figure 9](#fig9){ref-type="fig"}).10.7554/eLife.15635.030Figure 9.Sashimi plots of the *Sox9* and *Sox8* genes in mutant and control conditions.Vertical lines indicate coverage and curved lines indicate splicing. The mm10 row shows the positions of the exons and introns and the translated region as annotated in the mm10 UCSC mouse genome. Aberrant splicing sites where found in mutant but not in control samples. Notice that normal splicing also occurred in mutant animals showing that CRE-recombination efficiency was not 100%.**DOI:** [http://dx.doi.org/10.7554/eLife.15635.030](10.7554/eLife.15635.030)

For *Sox9/8* DKO and *Dmrt1* KO transcriptome comparison CEL files corresponding to the *Dmrt1* conditional knockout expression analysis of P28 testes by [@bib28] were downloaded from the GEO database (Acc: GSE27261). Files were processed with the simpleaffy ([@bib31]) package from Bioconductor and normalized with gcrma ([@bib58]). Uninformative data, control probes and genes with low variation or close to background were filtered out. Data were grouped in two conditions, Control and Mutant. Differential expression was analyzed with the limma package ([@bib41]) and annotated with the Affymetrix Mouse Genome 430 2.0 Array annotation data. Genes with log~2~FC having p values less than 0.05 for differential expression tests respect to normal testes where selected. These genes list was then selected from our transcriptome data and those showing non-significative log~2~FC where filtered out. The remaining 8910 genes showing significant differential expression in both experiments are included in [Figure 5---source data 1](#SD3-data){ref-type="supplementary-material"}.
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###### Complete lists of genes included in the 8 molecular pathways mentioned in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.

**DOI:** [http://dx.doi.org/10.7554/eLife.15635.031](10.7554/eLife.15635.031)

Major datasets {#s7}
--------------

The following dataset was generated:

Barrionuevo FJ,Hurtado A,Kim GJ,Real FM,Bakkali M,Kopp JL,Sander M,Scherer G,Burgos M,Jimenez R,2016,Testis-to-ovary reprogramming and testis regression after ablation of Sox9 in Sox8-/- mice,<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4572/>,Publicly available at the European Bioinformatics Institute Array Express (Accession no: E-MTAB-4572)

The following previously published dataset was used:

Matson CK,Murphy MW,Sarver AL,Griswold MD,Bardwell VJ,Zarkower D.,2011,Dmrt1 (doublesex and mab-3 related transcription factor 1) conditional knockout expression analysis of P28 testes,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27261>,Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE27261)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"*Sox9* and *Sox8* protect the adult testis from male-to-female genetic reprogramming and complete degeneration\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Janet Rossant as the Senior Editor. One of the three reviewers has agreed to reveal his identity: Steven Munger (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Over the past few years, a new concept appears in reproductive biology showing that the sexual fate of adult supporting cells in male and female gonads is not fully determined and that transdifferentiation of granulosa to Sertoli can occur. The effect of adult knock-out of both *Sox9* and SOX8 was clearly awaited, given the known key roles of these genes in establishing testis fate in development. Overall this manuscript reports a tremendous amount of work with the characterization of mutant gonads at many different time-points after P60 by histology, immunohistochemistry using many relevant cell markers, and transcriptomic analyses by RNA-sequencing at one developmental stage. The results are detailed, well illustrated, well reported and convincing. The results presented here are novel and are of broad interest in understanding transdifferentiation and the stability of adult differentiated cell types

Essential revisions:

The reviewers raised a few essential points that need to be addressed in a revised manuscript:

1\) Better explanation of TX administration and timeline; inclusion of diagram to outline dosage details. Address potential indirect reproductive effects from TX.

2\) Include Excel table of differential expression comparison from RNA-seq.

3\) Moderate any conclusions made on the basis of weak double staining in confocal images.

These are detailed below.

1\) In the present study, authors have mainly characterized testes after a 3 months exposure to tamoxifen (introduced in the food as stated in the subsection "Tamoxifen administration"), stage named P150 (90 datx). By contrast, in an equivalent study on *Dmrt1*, Matson and colleagues treated P60 mice, carrying the UbiquitinC-cre/ERT2, by only two IP-injections of 4mg tamoxifen/mouse (Matson et al., 2011, Nature 476:101-4). And surprisingly here, after the 3-months TX-treatment the *Sox9* gene is far to be completely deleted as presented on Supplemental Materials and methods, first paragraph (with apparently a better efficiency of the *Sox9-Cre* compare with the Wt1-cre; fitting with results presented in the first paragraph of the Results section). Do the authors have an idea to explain this poor efficiency of this TX-treatment? And how are they sure to study double KO *Sox8/9* testes?

As tamoxifen is a selective estrogen-receptor modulator, its action per se remains questionable, especially on reproductive organs. A negative answer to this question could emerge from transcriptomic data ([Figure 2B](#fig2){ref-type="fig"}, as example) where TX-treated control and control testis present the same transcriptomic profile. But, uncertainty remains for TX-treatment and an eventual discrepancy between control and mutant animals. As example: it remains difficult to understand if a stage named P150 (90datx) corresponds (i) to a mouse with tamoxifen during 90 days after P60 or (ii) with tamoxifen during 30 days (from P60 to P90) then without tamoxifen from P90 to P150. In the latter case it has been better to note the stage P150 (30 datx + 60) instead of P150 (90 datx). Confusion about this arises in subsection "Transcriptome analysis" compared with the subsection "Somatic testis-to-ovary genetic reprogramming in the absence of *Sox9* and *Sox8* in adult mouse testes"; and also from sentences in the subsection "Tamoxifen administration" compared with the legend to [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} (\"P150 (60 datx)\"); and also from the first paragraph of the Results section. Authors should clarify this point all along the text, the figures and the legends of the figures. Moreover, all along the manuscript authors write \"TX-treated controls\" instead of writing \"PXX (ZZ datx)-control\" where XX will represent the stage of observation (from 70 to 180) and ZZ the duration of TX-treatment. Authors should indicate in each case how long TX has been administered to control animals. Authors should also indicate the genotype of the control. Normally, the best control of a *Sox9^flx/flx^;Sox8^-/-^;Sox9-CreERT2*-P150 (90 datx) will be a *Sox9^flx/flx^;Sox8^-/-^*;Control-P150 (90 datx). Is it the case?

[Figure 5](#fig5){ref-type="fig"} -- One concern I have is that the authors may be over interpreting the observed positive linear trend in their comparison of differentially expressed gonad genes from their current (RNA-seq based) *Sox9/8* dco study at P150 to an earlier published microarray analysis of SC-*Dmrt1*KO testes at P28 (Matson et al. 2011). The authors conclude that *Dmrt1* and *Sox9/8* likely act in the same pathway because nearly all genes strongly affected by loss of *Dmrt1* were also affected by the loss of *Sox9/8*. Although I agree this is likely to be true, this pattern of gene expression could be a secondary effect of the change in relative numbers of cell types in these whole gonad samples. Any gene KO that results in loss of Sertoli cells will likely cause this change in the observed expression pattern of known sex-determining genes regardless of which specific pathway they are affecting in the Sertoli cell.

2\) This was requested by one of the reviewers to assist with analysis of data.

3\) [Figure 4](#fig4){ref-type="fig"} also shows double \"weak staining\" and in contrast with [Figure 3](#fig3){ref-type="fig"}, [Figure 4A](#fig4){ref-type="fig"} provides only merge for SOX9 and FOXL2, the single colors for each staining should be added to convince the reader. Same observation for DMRT1/FOXL2 double staining ([Figure 4D](#fig4){ref-type="fig"} b and b\'). These double staining are the weak point of the manuscript because the authors make from these experiments some important conclusions. It would be helpful for the reader if the authors could bring some counting of these \"double stained cells\" to support their conclusions.

10.7554/eLife.15635.037

Author response

*Essential revisions:*

The reviewers raised a few essential points that need to be addressed in a revised manuscript:

*1) Better explanation of TX administration and timeline; inclusion of diagram to outline dosage details. Address potential indirect reproductive effects from TX.*

The reviewers were concerned about four main issues:

A\) The administration of the tamoxifen (TX) treatment and the notation we used to refer to the analyzed stages;

B\) The CRE recombination efficiency;

C\) The possible collateral effects that TX could have had on the phenotype of our control and mutant mice;

D\) Our interpretation of the results when comparing our RNA-seq data with those from the microarray analysis of SC-*Dmrt1*KO P28 testes performed by Matson et al. (2011).

A\) Regarding the tamoxifen treatment, the reviewers stated that the "authors have mainly characterized testes after a 3 months exposure to tamoxifen".

This is a clear confusion as in the Results section and Materials and methods section of our first version of the manuscript it was indicated that diet treatment lasted for 30 days/one month. We initially treated adult mice with TX at a concentration of 30mg/ml and 0.16 mg of TX per gram of body mass using a feeding needle for 5 consecutive days. However, *Sox9/8* double mutants displayed 90% lethality with this treatment. This is probably related to the fact that *Sox8^-/-^* mice display an idiopathic body mass reduction and are weaker than WT ones, as reported previously (Sock et al., 2001. Idiopathic weight reduction in mice deficient in the high-mobility-group transcription factor *Sox8*. Mol Cell Biol. 21: 6951--6959). Then, we reduced the dose of TX (down to 0.07 mg TX / gr of body mass) and 90% of *Sox9/8* double mutants survived, but the efficiency of CRE recombination in adult Sertoli cells fell then to below 20%. Since acute/short TX treatments were clearly useless in our animal model, we then tried to feed mice with a TX-supplemented diet (40mg TX/100g Harlan 2914 diet) for one month (never for three months).

TX administration always started at 2 months (postnatal stage P60) and finished just 30 days later (at P90). Thus, a stage named "P150 (90 datx)" (datx: days after TX treatment initiation) corresponds to a mouse treated for 30 days with TX-supplemented diet (from P60 to P90) and fed afterwards with normal diet, from P90 to P150. This treatment resulted in a 100% survival rate and permitted us to induce outstanding phenotypes in the mutant animals. So, all the data presented in the manuscript, except those shown in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and 3 (see below for an explanation), were obtained from mice treated with the TX-supplemented diet as described (one month).

We assume that, like the reviewers, any other reader could also be confused regarding TX-treatment and admit that our ms was not clear enough in this respect. For this reason, as suggested by the editors, we have included a diagram in [Figure 1](#fig1){ref-type="fig"} (the new [Figure 1A](#fig1){ref-type="fig"}) illustrating the experimental schedule of the TX treatment and explaining how we have noted the main stages analyzed in the study. In our opinion, including this information at the very beginning of the Results section will ensure to make this point definitely clear. Hence, we believe that our original notation of the analyzed stages \[P150 (90datx), for instance\] will now be easily understandable for the reader, so we decided to keep it as it stands. Nevertheless, we would change the notation as suggested by the reviewers \[P150 (30 datx + 60), for instance\] if the editor/reviewers still consider that this system is better.

The reviewers also had some concerns regarding the TX-treated controls. Control animals shared the same cages and diet with mutant ones, so both control and mutant mice received exactly the same treatment. So, we do not see the need and convenience of using a different notation for them. The treatment of control animals was always indicated in the figures and in the figure legends. For instance, in the frame at the top of Figure 1Bb (the new one) it is simply noted Control, but in another frame placed just below it is noted the stage \[P150 (90 datx)\] which evidences that both control and mutants were treated with TX in the same way. The same system was used in all figures. In addition to the mutant samples, we always placed testis sections from four control animals in our IFs and IHCs histological preparations: WT (both TX-treated and untreated) and *Sox9^f/f^;Sox8^-/-^* (both TX-treated and untreated). Notably, we never found a significant difference between them in the expression pattern of any of the markers we analyzed in this study. Moreover, the micrographs we selected to be included in the figures were always from the TX-treated *Sox9^f/f^;Sox8^-/-^* mice. Nevertheless, following the reviewers' recommendations, we have included in the figure legends the genotype of every control mouse that was not explicitly mentioned in the text.

Similarly, changes have been made in several points of the text (subsection "Somatic testis-to-ovary genetic reprogramming in the absence of *Sox9* and *Sox8* in adult mouse testes", first paragraph, subsection "Tamoxifen administration" and subsection "Transcriptome analysis"), for which the reviewers reported some confusion on TX treatment.

[Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and 3 report data from the only experiments in which mice were not treated with a TX-supplemented diet (see above). Instead, TX was administered orally with a feeding-gauge needle. We started using the WT1-CRE line to generate the SC *Sox9/8* DKO mice, and TX was initially administered either intraperitoneally or with a feeding-gauge needle (we obtained better results with the feeding needle). All control and mutant mice with compound homozygous and heterozygous genotypes containing less than 2 *Sox8* null alleles (either 0 or 1) tolerated well the TX treatment, but those containing 2 *Sox8* null alleles exhibited high lethality, permitting us to analyze only some few surviving animals. Nevertheless, the fact is that the results obtained in those initial studies clearly show the redundancy between *Sox9* and *Sox8* in adult testis maintenance, and we considered unnecessary and inappropriate to sacrifice so many additional animals for simply repeating the same experiment using the TX-supplemented diet. This is why we included the following sentence in our first version of the manuscript: "All results presented here, except those included in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}, were obtained from mice fed with the TX-supplemented diet."

According to these considerations, and in order to avoid any confusion in the rest of the manuscript, we have made changes in the text as shown in legends of [Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

The reviewers also expressed some concern regarding the sentence in the first paragraph of the Results section, but we believe that with the above changes this sentence is actually not confusing in the new version.

B\) Regarding TX, the reviewers had another concern related to the presumed low efficiency of our treatment system, compared with that used by Matson et al. (2011, Nature 476:101-104).

As far as we know, no paper has reported to date a TX-induced CRE recombination in adult mouse Sertoli cells showing an efficiency higher than the one we present here. Matson and col. used Ubc-CRE/ERT2 mice to delete *Dmrt1* in adult mice and they observed that after TX injection DMRT1 expression declined rapidly in germ cells while remained constant in Sertoli cells over the following 8 days (Matson et al., 2010) The mammalian doublesex homolog DMRT1 is a transcriptional gatekeeper that controls the mitosis versus meiosis decision in male germ cells. Dev. Cell 19, 612--624\]. In the 2011 work, they used the same mice and the same treatment, and they were able to show just a few (only 4) FOXL2+ cells within a testis cord one month after TX administration, evidencing a very low recombination efficiency in Sertoli cells. Actually, no data about the efficiency or kinetics of CRE recombination in Sertoli cells was reported in that paper. Other studies have also revealed that TX-induction of CRE-mediated recombination in adult Sertoli cells it is not an easy task with the available tools. For example, conditional inactivation of Wt1 using a CAG-CRE, revealed efficient recombination in kidney, ovary, pancreas, spleen, lung, and uterus, but not in Sertoli cells (Chau, You-Ying et al., 2011). Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1. PLoS Genet 7.12: e1002404\]. Here we show that the number of SOX9+ cells per seminiferous tubule cross section decreased to 37% in the testes of the *Wt1- Cre-ERT2; Sox9^f/f^;Sox8^-/-^* mice and to 69% in the *Sox9-Cre-ERT2;Sox9^f/f^; Sox8^-/-^* testes when compared to controls (new [Figure 1B](#fig1){ref-type="fig"}). This reduction is even more pronounced if we compare the Sashimi plots for *Sox9* obtained from our transcriptome data (see supplemental Materials and methods), which show a reduction of the WT *Sox9* transcripts of 57% and 80% for the *Wt1-Cre* DKO and the *Sox9-Cre* DKO lines, respectively. Thus, we disagree with the notion that we managed with low CRE recombination efficiency in our experiments. Rather, we believe we were able to develop a TX administration schedule that provides the highest CRE recombination efficiency reported to date in Sertoli cells (demonstrated with two different mouse CRE lines). We consider that this method could be a valuable tool for future gene targeting studies in adult Sertoli cells.

Based on the presumed low efficiency of CRE recombination, the reviewers asked: "how are they (the authors) sure to study double KO *Sox8/9* testes"? We are absolutely sure we studied double KO *Sox8/9* testes for two reasons:

1\) We have used a *Sox8^-/-^* mouse in which the WT SOX8 protein is absent, as reported previously (Sock et al., 2001) Idiopathic weight reduction in mice deficient in the high-mobility-group transcription factor *Sox8*. Mol Cell Biol. 21: 6951--6959\]. Consistent with this, the Sashimi plots for *Sox8* obtained from our transcriptome data (see Supplemental Materials and methods) show that in the *Sox8^-/-^* mice, *Sox8* transcripts only conserve the 5' untranslated region, demonstrating that these individuals are actually homozygous for a *Sox8* null allele.

2\) The Sashimi plots for *Sox9* confirm that, as expected according to the features of the *Sox9^flox^* line we used (Kist et al. (2002). Conditional inactivation of *Sox9*: a mouse model for campomelic dysplasia. Genesis 32: 121--123\], CRE recombination generates *Sox9* transcripts lacking the 2nd and 3rd exons. In addition, our IF studies demonstrated that the SOX9 protein is highly reduced in the SC *Sox9/8* adult testes after TX administration ([Figure 1B](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

C\) "Address potential indirect reproductive effects from Tx".

Two previous studies have investigated the effect of TX on male fertility on rats: 1) Gopalkrishnan, et al. (1998) Tamoxifen-induced light and electron microscopic changes in the rat testicular morphology and serum hormonal profile of reproductive hormones. Contraception, 57: 261-269; and 2) Gill-Sharma et al., (1993) Effects of tamoxifen on the fertility of male rats. J. Reprod. Fertil. 99: 395-402. In these studies, TX was administered during 90 days at different concentrations: 0.04, 0.2 and 0.4 mg TX /gr body weight/day. The authors observed a progressive degeneration of the germinative epithelium already detectable by day 10 after TX administration. By day 50, the phenotype was quite severe, with prominent reduction of the germinative epithelium thickness and low numbers of spermatids and spermatozoa. The severity of this phenotype increased with the TX concentration.

Importantly, they also showed that this reduced fertility was completely restored 90 days after drug withdrawal. We have administered to our mice a dosage equivalent to the lowest used in these studies (0.04 TX /gr body weight/ day). In fact, we supplemented our diet with 40 mg TX/100 mg food; a 25 mg mouse eats around 3 gr of food per day and our mice were fed only for 30 days with this diet. We described the effect of this concentration of TX:: "TX-treated controls were similar to untreated males, except between P80 (20 datx) and P120 (60 datx) and mainly at P90 (30 datx), when they showed some degenerating seminiferous tubules, but recovered afterwards". Additional related information is provided in [Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}.

Indeed, at the histological level, P90 (30 datx) testes showed degenerating seminiferous tubules, and the number of spermatozoa was reduced, but at P120 (60 datx) control testes showed almost no difference with the testes of P120 untreated males. At P150 we found no difference between treated (90 datx) and untreated testes. At this later stage, transcriptome comparison showed no difference between TX-treated and untreated testes. In addition, we found no difference in the expression pattern of several proteins analyzed by IHC and IF between TX-treated and untreated controls at any stage.

Thus, we are confident that TX treatment did not affect the results of our study on *Sox9/8* mutant mice.

D\) Another concern of the reviewers was that "the authors may be over interpreting the observed positive linear trend in their comparison of differentially expressed gonad genes from their current (RNA-seq based) *Sox9/8* dco study at P150 to an earlier published microarray analysis of SC-*Dmrt1*KO testes at P28 (Matson et al. 2011)".

We believe the reviewers are correct. A possibility remains that the coincident gene expression pattern observed in these two profiling studies could also have been a secondary effect of the changes in the relative numbers of cell types occurred in both cases. Accordingly, we have changed the text in order to include this possibility (see subsection "Sertoli-to-granulosa cell transdifferentiation is mediated by *Dmrt1* downregulation in *Sox9/8* SC-DKO testes", second paragraph). We observed that nearly all genes strongly affected by the loss of *Dmrt1* were also affected by the loss of *Sox9/8*, with a regression line whose scope is nearly 1. Based on this, we stated that these results suggest that "both *Dmrt1* and *Sox9/8* act in the same pathway". But this is just another finding in support of this hypothesis, not the only one. Additional supporting evidence exist: 1) in both *Sox9/8* and *Dmrt1* mutants, *Foxl2* is upregulated; 2) *Sox9/8* ablation leads to *Dmrt1* downregulation; 3) *Dmrt1* ablation leads to *Sox9/8* downregulation; and 4) in both *Sox9/8* and *Dmrt1* mutants, RA-signaling pathway is affected. Overall, available evidence supports the notion that these two genes act in the same pathway in Sertoli cells.

2\) Include Excel table of differential expression comparison from RNA-seq.

We have included the differential expression comparison from RNA-seq in [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}, we made a call to this file in the subsection "Somatic testis-to-ovary genetic reprogramming in the absence of *Sox9* and *Sox8* in adult mouse testes", and we have included a legend.

*3) Moderate any conclusions made on the basis of weak double staining in confocal images.*

The single color channels for [Figure 4A and D](#fig4){ref-type="fig"} were already included in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} of the first version of the manuscript. In a former revised version of this manuscript submitted to another journal, we composed a different [Figure 4](#fig4){ref-type="fig"} including the single color channels for [Figure 4A and D](#fig4){ref-type="fig"}. However, one of the reviewers' concerns was that the resulting figure was overwhelming. That is why in this version of the manuscript we decided to include the single channels in a supplemental figure. As suggested by the *eLife* reviewers, we have counted 203 FOXL2+ cells from 4 animals at P120 (60 datx) and 12 of them coexpressed SOX9. Likewise, we counted 127 FOXL2+ cells from 4 animals at P120 (60 datx) and 16 coexpressed DMRT1. We changed the text accordingly in the first paragraph of the subsection "Sertoli-to-granulosa cell transdifferentiation is mediated by *Dmrt1* downregulation in *Sox9/8* SC-DKO testes".
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